1. Academic Validation
  2. Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential

Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential

  • bioRxiv. 2023 Jul 31:2023.07.29.551106. doi: 10.1101/2023.07.29.551106.
Jason Wallach 1 Andrew B Cao 2 Maggie M Calkins 2 Andrew J Heim 3 Janelle K Lanham 2 Emma M Bonniwell 2 Joseph J Hennessey 2 Hailey A Bock 2 Emilie I Anderson 2 Alexander M Sherwood 4 Hamilton Morris 1 Robbin de Klein 5 Adam K Klein 6 Bruna Cuccurazzu 6 James Gamrat 1 Tilka Fannana 1 Randy Zauhar 3 Adam L Halberstadt 6 5 John D McCorvy 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, Saint Joseph's University, Philadelphia, Pennsylvania 19104, United States.
  • 2 Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
  • 3 Department of Chemistry, Saint Joseph's University, Philadelphia, Pennsylvania 19104, United States.
  • 4 Usona Institute, Madison, Wisconsin, 53711, United States.
  • 5 Research Service, VA San Diego Healthcare System, San Diego, California 92161, United States.
  • 6 Department of Psychiatry, University of California San Diego, La Jolla, California 92093, United States.
Abstract

Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT2A-Gq/11 and β-arrestin2 signaling, making their respective roles unclear. To elucidate this, we developed a series of 5-HT2A-selective ligands with varying Gq efficacies, including β-arrestin-biased ligands. We show that 5-HT2A-Gq but not 5-HT2A-β-arrestin2 efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT2A partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT2A-Gq efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT2A agonists. We also demonstrate that β-arrestin-biased 5-HT2A receptor agonists induce receptor downregulation and tachyphylaxis, and have an anti-psychotic-like behavioral profile. Overall, 5-HT2A receptor signaling can be fine-tuned to generate ligands with properties distinct from classical psychedelics.

Figures
Products